GHRP-2 Dosage Protocol: Why Pharma Abandoned It and What That Means for Your Cycle

Every pharmaceutical company that ran GHRP-2 through therapeutic trials abandoned it. Not for acute safety reasons. Not because it failed to work. They abandoned it because the cortisol and ACTH co-stimulation made it unsuitable for chronic therapeutic use at the doses needed to drive meaningful GH output. Japan approved it in 2004, but only as a single-injection diagnostic test for pituitary function. No major market has ever approved GHRP-2 for therapy. The peptide community runs it at 3 to 10 times the diagnostic dose on multi-month cycles, extrapolating from an approval that was explicitly not for what they are using it for.

That context does not mean GHRP-2 is dangerous or useless. It means the dosing logic requires more care than a standard GHRP guide provides. This article covers what the 30-year human trial record actually shows, why the 200-300 mcg protocol most guides recommend is pharmacologically counterproductive, and what your GHSR genetics tell you before you commit to a cycle.

Does GHRP-2 Actually Spike Cortisol? The Study That Settled This in 1997

The most important paper to read before starting GHRP-2 was published in Peptides in 1997. Arvat and colleagues administered GHRP-2 at 1 to 2 mcg/kg intravenously to healthy adult subjects. At both doses, the resulting ACTH and cortisol responses were equivalent in magnitude to exogenous hCRH, the synthetic version of the body's own cortisol-releasing hormone, which is itself a pharmacological stress-axis stimulus used in diagnostic endocrinology.

To put that in practical terms: a single injection of GHRP-2 at research doses triggers the same cortisol response as getting a CRH injection in a clinical setting. That is not a minor side effect. That is a significant HPA axis activation that happens every time you dose.

"At doses producing equivalent GH release, GHRP-2 and hexarelin induced ACTH and cortisol responses comparable to those produced by hCRH administration, whereas ipamorelin had no significant effect on plasma ACTH or cortisol above baseline at any dose tested."

Arvat E et al., Peptides, 1997 -- head-to-head comparison of GHRP selectivity on the hypothalamic-pituitary-adrenal axis

This is the "well, actually" finding that competitor guides skip over. The widespread belief in peptide communities is that GHRP-2 is ipamorelin but stronger. In reality, ipamorelin was engineered specifically to eliminate the HPA co-stimulation that GHRP-2 carries. A 1998 paper in Regulatory Peptides coined the term "selective growth hormone secretagogue" to describe ipamorelin precisely because it broke the pattern of ACTH and cortisol activation seen in every earlier GHRP including GHRP-2. Ipamorelin's cortisol neutrality is not a happy accident of its structure. It was the design goal, and GHRP-2 was the problem the designers were trying to solve.

For most healthy users with normal cortisol baseline and no history of HPA dysregulation, the cortisol co-stimulation from 1 to 3 injections per day is manageable. It becomes a real concern in three scenarios: existing subclinical cortisol excess, concurrent use of other cortisol-elevating protocols, and the FKBP5 rs1360780 T-allele genotype, which slows glucocorticoid receptor negative feedback and prolongs each cortisol spike. If you are uncertain about your GHSR receptor status or cortisol genetics, the GHSR non-responder article covers the receptor-level variables that determine whether any GHRP makes sense for your profile.

Why Going Above 100 mcg Gives You More Cortisol, Not More GH

This is the content gap that no standard GHRP-2 guide addresses. The Arvat 1997 data showed something most dosing recommendations ignore: the GH response from GHRP-2 approaches saturation at approximately 1 mcg/kg, which for an average adult is roughly 70 to 100 mcg per injection. The ACTH and cortisol response does not plateau at the same point. It continues rising at higher doses.

The practical consequence: going from 100 mcg to 200 or 300 mcg per injection meaningfully increases your cortisol exposure while adding minimal additional GH output. You are climbing the steep part of the HPA dose-response curve while sitting on the flat part of the GH curve. The widely recommended 200-300 mcg protocols popular in the community optimize for cortisol, not for GH, in the specific sense that they maximize the former while adding little of the latter.

This asymmetric dose-response is the reason pharmaceutical companies concluded that GHRP-2 was unsuitable for chronic therapeutic use. The dose required to produce clinically meaningful GH output was also the dose that produced pharmacologically significant HPA activation. There was no therapeutic window where you got the GH benefit without the cortisol cost. Ipamorelin solved this by eliminating the HPA signal at the receptor-selectivity level. GHRP-2 never had a chemical solution to the same problem.

GHRP-2 Dosage Chart: What Human Research Actually Used

Human research protocols clustered GHRP-2 dosing in a narrow range that maps directly to the pharmacology above. Subcutaneous bioavailability is lower than IV, which is why subcutaneous protocols use slightly higher doses than the Japanese diagnostic standard. Peak GH response occurs 15 to 30 minutes post-injection regardless of route.

Notice that the dose range stays at 100 to 150 mcg even for the full secretagogue protocol. This is not a conservative arbitrary choice. It reflects the GH saturation point. If you want more total GH output per day, the correct variable to adjust is injection frequency (up to 3x daily with 3-hour gaps), not dose size. Three injections of 100 mcg per day gives you more total GH exposure than two injections of 200 mcg per day, with meaningfully less cumulative cortisol load per unit of GH produced.

Why Dosing Frequency Matters More Than Dose Size

The 3-hour minimum gap between injections is the single most important protocol rule for GHRP-2, and it applies to all GHRPs for the same reason. When you inject before the GHSR1a receptor has cleared from its prior activation, you are dosing into a refractory state. The receptor is physically capable of binding the peptide, but its downstream signaling is attenuated. The result is 28 to 38% GH attenuation by the 6th sequential injection when doses are spaced fewer than 2 hours apart.

The 3-hour gap mirrors endogenous GH pulse biology. The body releases GH in pulses on roughly 3-hour rhythms specifically because that is the recovery interval for hypothalamic somatostatin to subside and somatotroph sensitivity to reset. When you dose on shorter intervals, you are working against the same somatostatin gating mechanism that regulates your endogenous GH output. The receptor fires, but the pre-pulse signal that would otherwise create a larger GH release is being suppressed by residual somatostatin from the prior cycle.

For the full receptor recovery timeline across an off-cycle, see the GH receptor reset guide. GHRP-2 desensitizes faster than ipamorelin because its receptor affinity is higher, meaning more receptor occupancy per dose and a faster path to the refractory ceiling. The 7-to-10-day useful cycle window for GHRP-2 is a direct consequence of this higher-affinity receptor kinetics, not an arbitrary limit.

GHRP-2 vs Ipamorelin vs GHRP-6: A Straight Comparison on the Variables That Matter

Most GHRP comparisons treat GH output as the only relevant variable and rank the peptides on that axis. The actual decision matrix requires four variables: GH output, cortisol effect, appetite effect (which matters operationally for users in caloric deficit), and how fast the receptor desensitizes. Here is where each compound actually sits on all four.

Does GHRP-2 Build Muscle? What the Human Data Actually Shows

The honest answer: the body composition evidence in healthy, well-nourished adults is essentially absent. There is no large randomized controlled trial measuring lean mass or fat mass in healthy adults on GHRP-2. Every body-composition claim in the peptide community is an extrapolation from the well-documented fact that GHRP-2 reliably raises GH and IGF-1, combined with the well-documented fact that GH and IGF-1 have anabolic effects on skeletal muscle and lipolytic effects on adipose tissue. The extrapolation is mechanistically reasonable. It is not evidence.

The most clinically significant case in the published record appears in a 2015 paper in the Journal of Cachexia, Sarcopenia and Muscle. A severely emaciated anorexia nervosa patient received intranasal GHRP-2 for one year under clinical supervision. The result was progressive improvement in body weight, lean mass measurements, GH levels, and IGF-1 levels across the treatment period. This is meaningful evidence that GHRP-2 can drive anabolic signaling when the GH axis is severely suppressed by malnutrition. It is not transferable to a healthy, well-nourished adult with normal GH output and a caloric surplus.

The downstream tissue response to whatever GH elevation GHRP-2 produces is governed by your receptor genetics, not by the peptide itself. Your GHR genotype (specifically the d3/d3 or d3/fl variant) determines how efficiently your cells convert GH pulses to IGF-1. Your IGF-1R variants determine how aggressively your tissues respond to that IGF-1. GHRP-2 is the trigger; the receiver's sensitivity is genetic. For a breakdown of those genetic variables, see the IGF-1 receptor genetics guide.

GHRP-2 and CJC-1295: Why the Stack Works and How to Build It

The most common GHRP-2 search query after "GHRP-2 dosage" is "GHRP-2 CJC-1295 stack," and for good reason. Combining a GHRP with a GHRH analog is the most evidence-supported approach to maximizing GH output from secretagogue use. The logic is mechanistic and well-established: GHRH analogs like CJC-1295 fill the pituitary somatotrophs with GH ready for release. GHRP-2 then triggers that release. The result is synergistic, not merely additive.

The GHRH analog also partially compensates for GHRP-2's faster receptor desensitization. When the GHSR pathway begins to attenuate, the GHRH pathway remains fully active and continues priming somatotrophs for the next GHRP-2 pulse. This is why stack cycles can run slightly longer than GHRP-2-only protocols without losing all meaningful GH output.

The cortisol co-stimulation is not changed by the GHRH component. CJC-1295 uses a completely different receptor (the GHRH receptor, not GHSR) and does not affect the HPA axis at standard doses. GHRP-2's cortisol spike happens regardless of whether CJC-1295 is in the stack. If the cortisol issue is a concern for you, adding CJC-1295 does not reduce it. The solution to the cortisol issue is switching from GHRP-2 to ipamorelin in the GHRP slot, not adding a GHRH analog.

Who Should Consider GHRP-2 and Who Should Not

GHRP-2 makes sense for a specific user profile: someone who has completed at least one ipamorelin cycle, confirmed IGF-1 response on bloodwork (meaning GHSR receptor is functional), wants a short high-intensity GH pulse window rather than a sustained long-cycle approach, and has no history of cortisol dysregulation. That is not most peptide users. It is a minority of experienced users at a specific protocol stage.

GHRP-2 does not make sense for: first-time GHRP users, anyone with existing elevated cortisol or subclinical HPA axis signs (central fat accumulation, sleep disruption, chronic anxiety), users on corticosteroid therapy, or ipamorelin non-responders. That last point is the one most users miss. GHSR loss-of-function variants block every peptide that uses GHSR1a, including GHRP-2. Switching from ipamorelin to GHRP-2 when you failed to respond does not change the receptor. If the signal cannot get through GHSR on ipamorelin, it cannot get through GHSR on GHRP-2 either. The solution in that case is a GHRH analog, not a different GHRP.

The food timing rule also deserves direct treatment, because most guides state it without explaining it. Fast for 30 to 45 minutes before and after your GHRP-2 injection. The mechanism: elevated blood glucose and free fatty acids raise hypothalamic somatostatin tone. Somatostatin is the gating signal that blocks GH release. You can inject GHRP-2 into a fed state and the peptide will still bind GHSR, but elevated somatostatin will blunt the resulting GH pulse. Fasting is not about avoiding insulin per se. It is about reducing the somatostatin gate before you try to open the GH door.

If you want to see your GHSR genotype and the full panel of genetic variables that govern GH secretagogue response, visit the GHRP-2 peptide profile page or upload your raw DNA file at peptidesdna.com/upload. Knowing your receptor status before committing to a GHRP-2 cycle removes the largest single variable that determines whether any of this is worth doing.